Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk by Touvier, M et al.
promoting access to White Rose research papers
White Rose Research Online
eprints@whiterose.ac.uk
Universities of Leeds, Sheffield and York
http://eprints.whiterose.ac.uk/
This is the Author's Accepted version of an article published in Cancer
Epidemiology, Biomarkers and Prevention
White Rose Research Online URL for this paper:
http://eprints.whiterose.ac.uk/id/eprint/78299
Published article:
Touvier, M, Chan, DS, Lau, R, Aune, D, Vieira, R, Greenwood, DC, Kampman, E,
Riboli, E, Hercberg, S and Norat, T (2011) Meta-analyses of vitamin D intake, 25-
hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal
cancer risk. Cancer Epidemiology, Biomarkers and Prevention, 20 (5). 1003 -
1016. ISSN 1055-9965
http://dx.doi.org/10.1158/1055-9965.EPI-10-1141
 1
Meta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor 1 
polymorphisms and colorectal cancer risk1 2 
 3 
Mathilde Touvier1,2, Doris SM Chan1, Rosa Lau1, Dagfinn Aune1, Rui Vieira1, Darren C Greenwood3, 4 
Ellen Kampman4, Elio Riboli1, Serge Hercberg2, Teresa Norat1 5 
Affiliations: 6 
1 Department of Epidemiology and Biostatistics, School of public health, Imperial College London, 7 
United Kingdom 8 
2 Nutritional Epidemiology Unit, UREN (Inserm/Inra/Cnam/Paris13 University), CRNH IdF, Bobigny, 9 
France 10 
3 Biostatistics Unit, Centre for Epidemiology and Biostatistics, University of Leeds, Leeds, United 11 
Kingdom 12 
4 Division of Human Nutrition, Wageningen University and Research Centre, Wageningen, The 13 
Netherlands 14 
Running title: Meta-analyses of vitamin D and colorectal cancer 15 
Key words: Colorectal cancer, vitamin D, meta-analysis, polymorphisms, 25-hydroxyvitamin D 16 
17                                                  
1  
Grant support: This work was supported by the World Cancer Research Fund as part of the Continuous Update Project (Grant 
Number: 2007/SP01). The views expressed in this review are the opinions of the authors. They may not represent the views of 
World Cancer Research Fund International/ American Institute for Cancer Research and may differ from those in future 
updates of the evidence related to food, nutrition, physical activity and cancer risk. 
Requests for reprints: Mathilde Touvier, Department of Epidemiology and Biostatistics, School of Public Health, Imperial 
College London, St. Mary's Campus, Norfolk Place, Paddington, London W2 1PG, UK 
Email: m.touvier@imperial.ac.uk / Tel: +33 1 48 38 89 54 / Fax: +33 1 48 38 89 31 
Disclosure of Potential Conflicts of Interest: No potential conflicts of interest were disclosed.  
Acknowledgements: We thank the systematic literature review team at the Wageningen University for their contributions to 
the colorectal cancer database.  
 
 American Association for Cancer Research Copyright © 2011 
 on March 7, 2011cebp.aacrjournals.orgDownloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on March 4, 2011; DOI:10.1158/1055-9965.EPI-10-1141
 2
Abstract 18 
Background: Our objective was to conduct a systematic review and meta-analysis of prospective studies 19 
on colorectal cancer and vitamin D intake and 25-hydroxyvitamin D status, as part of the World Cancer 20 
Research Fund Continuous Update Project. We also aimed at conducting meta-analysis of all studies on 21 
colorectal cancer and vitamin D receptor (VDR) single-nucleotide polymorphisms. 22 
Methods: Relevant studies were identified in PubMed (up until June 2010). Inclusion criteria were 23 
original, peer-reviewed publications, with a prospective design (for studies on vitamin D intake or status). 24 
Random effects dose-response meta-analyses were performed on cancer incidence.  25 
Results: We observed inverse associations of colorectal cancer risk with dietary vitamin D (summary RR 26 
per 100 IU/day=0.95 95%CI: (0.93-0.98); 10 studies; range of intake (midpoints) = 39-719 IU/day) and 27 
serum/plasma 25-hydroxyvitamin D (RR per 100 IU/l=0.96 (0.94-0.97); 6 studies; range=200-1800 IU/l), 28 
but not with total vitamin D (5 studies). Supplemental (2 studies; range=0-600 IU/day) and total (4 29 
studies; range=79-732 IU/day) vitamin D intake and 25-hydroxyvitamin D status (6 studies; range=200-30 
1800 IU/l) were inversely associated with colon cancer risk. We did not observe statistically significant 31 
associations between FokI, PolyA, TaqI, Cdx2 and ApaI VDR polymorphisms and colorectal cancer risk. 32 
The BsmI polymorphism was associated with a lower colorectal cancer risk (RR=0.57 (0.36-0.89) for BB 33 
vs. bb, 8 studies). 34 
Conclusions: These meta-analyses support the evidence of an inverse association between vitamin D 35 
intake, 25-hydroxyvitamin D status and the BsmI VDR polymorphism and colorectal cancer risk. 36 
Impact: Improving vitamin D status could be potentially beneficial against colorectal cancer incidence.  37 
  38 
Word Count: 250 39 
 40 
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Introduction 42 
 Colorectal cancer (CRC) is the third most frequently diagnosed cancer worldwide, accounting 43 
for more than one million cases and 600 000 deaths every year (1). Understanding the role of diet, a 44 
modifiable risk factor, in colorectal carcinogenesis might inform primary prevention strategies. A 45 
substantial body of literature has addressed the relationship between vitamin D and CRC risk. This 46 
relationship has been studied using estimates of dietary, supplemental and total vitamin D intakes and 47 
circulating 25-hydroxyvitamin D level, a biomarker of vitamin D status reflecting both intake and 48 
synthesis related to sunlight exposure. 49 
 Regarding dietary vitamin D intake, the World Cancer Research Fund and American Institute 50 
for Cancer Research (WCRF/AICR) report in 2007 concluded that the evidence vitamin D protects 51 
against risk of CRC was limited suggestive (RR for 100 IU/d=0.99 95%CI=(0.97-1.00)) (2). Since then, 52 
five new prospective cohort studies on vitamin D intake and CRC have been published (3-7), 53 
substantially increasing the evidence base available, but no updated dose-response meta-analyses have 54 
been published on vitamin D intake. In 2009, Huncharek et al. performed a highest versus lowest meta-55 
analysis of vitamin D intake and CRC and observed no statistically significant results (8).  56 
Regarding serum/plasma 25-hydroxyvitamin D status and CRC risk, three dose-response meta-57 
analyses have been published (9-11), suggesting an inverse association. Since the most recent meta-58 
analysis, conducted by IARC in 2010 (9), new results from the Multiethnic Cohort (12) have been 59 
published. None of these published meta-analyses provided information on proximal and distal colon 60 
cancer subtypes. In addition, these articles did not investigate a potential non-linear dose-response 61 
relationship between 25-hydroxyvitamin D and CRC risk. This could be useful for determining if an 62 
optimal value for vitamin D status can be retained regarding CRC prevention, and/or for validating 63 
optimal levels proposed by some authors (13, 14). 64 
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The vitamin D receptor (VDR) is an intracellular hormone receptor that specifically binds the 65 
biologically active form of vitamin D (1,25-dihydroxyvitamin D) and interacts with specific nucleotide 66 
sequences of target genes to produce a variety of biologic effects (15). It has been hypothesized that for 67 
individuals with similar vitamin D intake or status, those having a less active VDR could present an 68 
increased susceptibility to colorectal cancer risk. However, the evidence to date has been inconclusive. 69 
Two reviews (16, 17) and two meta-analyses (18, 19) have been published on the topic. Since the 70 
publication of the most recent meta-analysis (18), several new studies have been published (20-22), 71 
including results from the EPIC study, based on more than 1200 CRC cases. In addition, this meta-72 
analysis focused on BsmI and FokI polymorphisms only; it did not observe overall statistically significant 73 
associations (18). 74 
Our objective was to conduct a systematic review and meta-analysis of prospective studies on 75 
CRC and vitamin D intake published up to June 2010, as part of the WCRF Continuous Update Project. 76 
We also conducted meta-analyses of prospective studies on CRC and 25-hydroxyvitamin D level, as well 77 
as studies on VDR single-nucleotide polymorphisms. This paper provides a complete and updated state of 78 
the art regarding vitamin D and CRC risk, including substantially increased evidence base since previous 79 
reviews, and complementary types of exposures (intake / biomarker / VDR polymorphisms). It includes a 80 
linear dose-response approach (key feature in the discussion of causality), as well as an investigation of a 81 
potential non linear dose-response trend for vitamin D status, which has never been meta-analyzed before. 82 
 83 
Subjects and Methods 84 
Search strategy and selection criteria 85 
The present review is part of the Continuous Update Project implemented by the WCRF/AICR 86 
and conducted at Imperial College London on the associations between food, nutrition, physical activity 87 
and the prevention of cancer. The complete protocol for the review is available on the WCRF website 88 
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(http://www.dietandcancerreport.org/cu/). Briefly, we updated the systematic literature review 89 
(http://www.dietandcancerreport.org/downloads /SLR/Colon_and_Rectum_SLR.pdf) with study results 90 
published through June 2010. We searched PubMed without any language restriction using the same 91 
search strategy that was used to retrieve papers for the WCRF/AICR report (2). The search terms (MeSH 92 
terms and text words) identified a broad range of factors on diet and nutrition. The full search strategy is 93 
available online (http://www.dietandcancerreport.org/cu/). We also hand-searched reference lists from 94 
retrieved articles, reviews and meta-analysis papers on the related topic. The search and data extraction of 95 
articles published up to June 2006 was conducted by several reviewers at Wageningen University, The 96 
Netherlands, during the systematic literature review for the WCRF/AICR report (2). The search, data 97 
selection and extraction from June 2006 to June 2010 were done by two reviewers at Imperial College 98 
London. 99 
Studies were included in this review if they reported original data on the association of colorectal, 100 
colon or rectal cancer incidence with vitamin D intake (dietary, supplemental, total), 25-hydroxyvitamin 101 
D status and VDR single-nucleotide polymorphisms and if they were based on a prospective design 102 
(cohort or nested case-control), for studies on vitamin D intake and status. For VDR polymorphisms, all 103 
nested case-control and case-control studies were included. Only published peer-reviewed studies were 104 
included. To include the studies in the meta-analyses, estimates of the relative risks with the 95% 105 
confidence intervals had to be available in the publication. For the dose-response analysis, a quantitative 106 
measure of exposure and the number of cases and person-years were also needed. When multiple papers 107 
on the same study were identified, the inclusion of results in the meta-analysis was based on longer 108 
follow-up, more cases recruited and completeness of the information required to do the meta-analyses. 109 
 110 
Data extraction 111 
For each relevant study, information on study characteristics, cancer site, description of exposure, 112 
results, and details of the adjustment for confounders were extracted and stored in a database. The search, 113 
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data selection and extraction were done by two reviewers. Ten percent of the work was double checked 114 
by an independent reviewer. 115 
 116 
Statistical analyses 117 
Random effects models, that consider both within-study and between-study variation (23) were 118 
used to calculate summary RRs and 95% CIs for the associations of colorectal, colon or rectal cancer 119 
incidence with vitamin D intake, 25-hydroxyvitamin D level, and VDR single-nucleotide polymorphisms: 120 
FokI (rs2228570), BsmI (rs1544410), PolyA (rs17878969), TaqI (rs731236), Cdx2 (rs11568820), ApaI 121 
(rs7975232). We used the most fully adjusted RR in the paper, provided they were not adjusted for factors 122 
potentially in the causal pathway. 123 
For vitamin D intake and biomarkers, linear dose-response, as well as highest vs. lowest meta-124 
analyses were conducted (23). We used the method described by Greenland and Longnecker (24) for the 125 
dose-response analysis to compute the trend from the correlated RRs and CIs across categories of 126 
exposure. We estimated, using standard methods (25), the distribution of cases or person-years in studies 127 
that did not report these and reported results by quantiles. In two studies (7, 26) in which the results were 128 
reported by functional categories and person-years by category were not reported, we used variance-129 
weighted least squares regression to estimate the trends. 130 
The median level of exposure in each category was assigned to the corresponding relative risk 131 
when reported in the study. If not reported, the value assigned was the mid-point of the lower and upper 132 
bound in each category. For extreme open-ended categories, half the width of the adjacent exposure 133 
category was subtracted (for the lowest category) or added (for the uppermost category) to obtain the 134 
mid-point. For studies that reported results separately for colon and rectal cancer, but not combined (27-135 
30), we combined the results using the Hamling procedure (31) to obtain an overall estimate for CRC; the 136 
same method was applied for distal and proximal colon cancer, to obtain an overall estimate for colon 137 
cancer (4). 138 
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Statistical heterogeneity between studies was assessed by the Cochran Q test and the I2 statistic 139 
(32). I2 values of approximately 25%, 50% and 75% are considered to indicate low, moderate and high 140 
heterogeneity, respectively. We also conducted linear meta-regression and stratified analyses by gender, 141 
number of cases, geographic location, ethnicity, range of exposure, adjustment for confounding factors 142 
such as calcium intake and sunlight exposure/season, and deviation from Hardy-Weinberg equilibrium 143 
(for studies on VDR polymorphisms) to investigate potential sources of heterogeneity. Small study bias 144 
such as publication bias was examined in funnel plots and by Egger’s test (33). The influence of each 145 
individual study on the summary relative risk was examined by excluding each in turn and pooling the 146 
rest.  147 
A potential non-linear dose-response relationship between dietary vitamin D intake and 25-148 
hydroxyvitamin D status and CRC was examined by using fractional polynomial models (34). 149 
A two-sided p<0.05 was considered statistically significant. All analyses were conducted using 150 
STATA version 9.2. 151 
  152 
Results 153 
Figure 1 presents the flowchart for study selection. We identified a total of 50 publications that 154 
examined the relationship between vitamin D intake and/or status (prospective studies) or VDR 155 
polymorphisms and CRC. Among these, eight publications were excluded from the meta-analyses: one 156 
was a component study of a multi-center cohort (35), two were superseded by more recent publications 157 
(36, 37), one restricted to cancer mortality as only outcome (38), one focused on VDR single-nucleotide 158 
polymorphisms that were not found in other publications on CRC risk (39) and three publications did not 159 
provide sufficient data to be included in the meta-analyses (22, 40, 41). Regarding the later three 160 
publications, only mean exposure data was provided in two of them: mean dietary vitamin D intake was 161 
either higher in non-cases than in CRC cases (40) or similar in both groups (41). The third publication 162 
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provided ORs of associations between CRC risk and heterozygous or homozygous mutant (grouped, but 163 
not separated) versus wild type, for several VDR single-nucleotide polymorphisms. No association was 164 
observed for the main VDR polymorphisms studied (i.e., BsmI, TakI and Cdx2) (22). Finally, 42 165 
publications have been included in the present meta-analyses on CRC incidence. Online supplementary 166 
Appendix 1 provides descriptive information on these studies. 167 
Otherwise mentioned below, there was no indication of publication bias with Egger’s test and 168 
sensitivity analyses excluding one study at a time did not substantially modify the findings. For vitamin D 169 
intake and status, results of dose-response meta-analyses are presented below, whereas results of highest 170 
versus lowest meta-analyses are presented in online supplementary Appendix 2. 171 
 172 
Vitamin D intake 173 
We observed a statistically significant inverse association between dietary vitamin D and CRC 174 
risk (Table 1, Figure 2A): summary RR=0.95 (95%CI: 0.93-0.98), for an increase of 100 IU/day (10 175 
studies included). Associations did not reach statistical significance for colon and rectum cancers 176 
separately (Table 1), nor for proximal and distal colon (data not shown). No statistical heterogeneity was 177 
detected except for rectal cancer, which was partly related to gender, as shown by meta-regression 178 
analysis (P=0.002). In stratified analyses, studies including more than 50% of women (5, 42, 43) showed 179 
a statistically significant inverse association between dietary vitamin D intake and rectal cancer (RR=0.78 180 
(0.67-0.90)), whereas studies including more than 50% of men (4, 26, 44) showed no association 181 
(RR=1.09 (0.84-1.40)) (data not tabulated). Available data was insufficient to conduct separate meta-182 
analyses by gender. Main sources of dietary vitamin D (i.e. dairy products (26, 42), fish (4, 44), or both 183 
(5, 43)) varied across studies. In the rectal cancer analysis, a higher RR (2.22 (0.99-4.97)) was observed 184 
for the Finnish Social Insurance Institution's Mobile Clinic (44) compared to other studies. In the 185 
corresponding publication (44), the authors stated that fish was the main contributor to dietary vitamin D 186 
intake, and that an increased CRC risk was associated with high consumption of salted and smoked fish in 187 
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this study. When this study was excluded from the analysis, the summary RR became 0.88 (0.77-1.02), 188 
and heterogeneity was reduced, but remained moderate (I2=45.7%, P=0.12). Restriction of the analyses to 189 
studies investigating both colon and rectum cancer sites did not modify the results (summary RR for 190 
colon became 0.97 (0.91-1.03) and was unchanged for rectum). There was no strong evidence of non-191 
linearity of the association between dietary vitamin D intake and CRC risk (p for non-linearity = 0.4), 192 
within the studied range of intake (midpoints of lowest and highest categories: 40-720 IU/d). 193 
No dose-response analysis could be performed for supplemental vitamin D and overall CRC due 194 
to insufficient data. However, two studies were available for dose-response meta-analysis of supplemental 195 
vitamin D and colon cancer specifically (27, 28), leading to a statistically significant inverse association 196 
(summary RR per 100 IU/day=0.93 (0.88-0.98)). 197 
The association between total vitamin D and CRC (Table 1, Figure 2B) was not statistically 198 
significant, with high heterogeneity and lower number of available studies compared to dietary vitamin D 199 
(five vs. ten). In sensitivity analyses excluding each study in turn, the summary RR for total vitamin D 200 
and CRC became statistically significant (0.97 (0.95-0.99)) and heterogeneity was substantially reduced 201 
(I2=36.5%, P=0.2) when the Women’s Health Study (45) was excluded from the analysis (data not 202 
tabulated). In sensitivity analyses restricted to the publications presenting results on both dietary and total 203 
vitamin D and CRC (7, 26, 42, 45) summary RRs were 0.93 (0.89-0.98) for dietary vitamin D and 0.99 204 
(0.95-1.02) for total vitamin D. We observed an inverse association between total vitamin D and colon 205 
cancer risk (RR per 100 IU/day=0.93 (0.90-0.98), but no association for rectal cancer (Table 1, Figure 206 
2B). In highest versus lowest meta-analyses, total vitamin D was inversely associated to both CRC 0.84 207 
(0.72-0.97) and colon cancer 0.71 (0.58-0.87) risk (Supplementary Appendix 2). 208 
 209 
25-hydroxyvitamin D level (biomarker of vitamin D status) 210 
We observed an inverse association between circulating 25-hydroxyvitamin D level and CRC risk 211 
(Table 1, Figure 2C) (RR per 100 IU/l=0.96 (0.94-0.97)). Results were borderline significant for colon 212 
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cancer (Table 1). We observed an inverse association between serum/plasma 25-hydroxyvitamin D and 213 
distal colon cancer (RR per 100 IU/l=0.91 (0.85-0.98), no heterogeneity: I2=0%, P=0.9, 3 studies 214 
included (46, 47), data not tabulated). Results were not statistically significant for proximal colon (data 215 
not shown) and rectum cancers (Table 1). In highest versus lowest meta-analyses, 25-hydroxyvitamin D 216 
level was also inversely associated to CRC risk 0.66 (0.52-0.84) (Supplementary Appendix 2). 217 
There was no strong evidence of non-linearity of the association between 25-hydroxyvitamin D 218 
and CRC risk (p for non-linearity = 0.087). The curve (Figure 3) suggested that increasing 25-219 
hydroxyvitamin D level was associated with a decreased risk of CRC in a linear dose-response manner, 220 
though a slight inflexion of the decrease in risk around the value of 1000 IU/l (24 ng/ml) could be 221 
suspected. The range of intake used in this analysis was 200-1800 IU/l (midpoints of lowest and highest 222 
categories). 223 
 224 
Vitamin D receptor polymorphisms 225 
The polymorphisms most often reported were BsmI and FokI. The BsmI polymorphism was 226 
associated with a lower CRC risk (RR for BB vs. bb=0.57 (0.36-0.89), 8 studies), with high heterogeneity 227 
(Table 1, Figure 4). The heterogeneity may be attributed to one study (48), for which deviation from 228 
Hardy-Weinberg equilibrium was observed. When we excluded it from the analysis, statistical 229 
heterogeneity was not detected (I2=0%, P=0.8) and the inverse association persisted, although weakened 230 
(RR for BB vs. bb=0.89 (0.81-0.98)). In the publication of Park et al. (49) no CRC case and only one 231 
control presented the BB genotype, thus, it was not possible to use those results in the meta-analysis. 232 
However, this study was included in the Bb vs. bb analysis (summary RR=0.81 (0.64-1.02), 9 studies). 233 
When this study (49) was excluded, the summary RR for Bb vs. bb became statistically significant: 0.77 234 
(0.61-0.98) (data not tabulated).  235 
We did not observe any statistically significant association for FokI VDR polymorphisms on ten 236 
studies (Table 1). Study results were highly heterogeneous. Results by gender were not provided in the 237 
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publications, thus separate meta-analyses on men and women were not possible. However, for ff and 238 
CRC, the only study including a higher proportion of women than men (50) showed a statistically 239 
significant positive association (RR=1.84 (1.15-2.94)), whereas studies including a higher proportion of 240 
men than women (19, 48, 51) or an equal proportion of men/women (21, 49, 52-55) showed no 241 
association (RR=0.95 (0.81-1.11), I2=33.1%, P=0.2 and 1.00 (0.49-1.03), I2=86.2%, p<0.0001, 242 
respectively) (data not tabulated). For ff and colon cancer, the risk ratios also increased with the 243 
proportion of women in the study: more men than women (56): 0.71 (0.57-0.87), equal proportion of 244 
men/women (21): 1.13 (0.80-1.58) and more women than men (50, 57): 2.0 (1.32-3.03). However, for this 245 
analysis on ff and colon cancer, Egger’s test (P=0.01) and funnel plot suggested a publication bias (i.e., 246 
inverse relationship between RR and study size). 247 
Five studies investigated TaqI (20, 49, 52, 55, 58) and Apa I (19, 20, 49, 52, 58) polymorphisms 248 
and CRC risk. No association was observed (Table I). From these, 4 studies also reported on BsmI (19, 249 
20, 49, 52) and 4 on Fok I (19, 49, 52, 55). High heterogeneity in the analyses on TaqI (tt vs. TT) and 250 
CRC was due to one study (55) with very small number of cases (n=26). No heterogeneity was detected 251 
when this study was excluded from the analysis (summary RR=1.07 (0.82-1.39), I2=0%). High 252 
heterogeneity was also observed in the analysis of ApaI (AA vs. aa) and CRC. Although ethnicity was not 253 
statistically significant in meta-regression (P=0.11), probably due to low statistical power, restriction to 254 
studies on Caucasian populations (19, 20, 52, 58) substantially decreased heterogeneity (RR=0.84 (0.68-255 
1.02), I2=29.6%, P=0.2). RR of the study on a non-Caucasian (Asian) population was 2.22 (1.12-4.40) 256 
(49). 257 
Four studies or less were identified on the PolyA and Cdx2 VDR polymorphisms. No association 258 
with CRC or colon cancer was observed, except a borderline significant positive association for Cc versus 259 
cc Cdx2 polymorphism and CRC (Table 1). 260 
 261 
 262 
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 263 
Discussion 264 
In dose-response meta-analyses, we observed inverse associations between dietary vitamin D and 265 
CRC risk and between supplemental and total vitamin D and colon cancer risk. The WCRF/AICR report 266 
in 2007 concluded a limited suggestive decreased risk of CRC for foods containing vitamin D (2). The 267 
present meta-analyses, including new results from five prospective cohort studies, add to the evidence for 268 
an inverse association between vitamin D intake and CRC risk. In a recent report (59), the American 269 
Institute of Medicine (IOM) has set at 600 IU/d the Recommended Dietary Allowance for vitamin D 270 
intake for most North Americans, except for people age 71 and older, who may require 800 IU/d. These 271 
recommendations were mostly based on the role of this nutrient in bone health. The order of magnitude of 272 
vitamin D intake studied in prospective observational studies on CRC and thus included in this dose-273 
response meta-analysis (maximal dose around 730 IU/d for total vitamin D), is consistent with IOM 274 
recommendations. 275 
Vitamin D status depends on intake from the diet and supplements but also on synthesis in the 276 
skin under the influence of sunlight. Thus, we also analyzed vitamin D status to obtain a better picture of 277 
the relationship between vitamin D and CRC risk. Consistent with results on vitamin D intake, we 278 
observed inverse associations between circulating 25-hydroxyvitamin D and colorectal and colon cancer. 279 
These findings update those of previous meta-analysis on 25-hydroxyvitamin D and CRC (9-11), 280 
suggesting the existence of an inverse association.  281 
The associations between polymorphisms in the VDR gene and CRC risk have been investigated 282 
in several publications, with inconsistent results, possibly because single studies may have lack statistical 283 
power. Except for BsmI and FokI, published studies on CRC and other VDR polymorphisms are scarce. 284 
The available evidence suggests that the BsmI polymorphism (BB) may be associated with a lower CRC 285 
risk. There was no statistical evidence of publication bias. This association, which strengthens the 286 
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evidence of the role of vitamin D in the etiology of CRC, requires confirmation in other studies. Beyond 287 
the potential effect of single-nucleotide VDR polymorphisms considered separately, their association in 288 
haplotypes (i.e. combinations of statistically associated single-nucleotide polymorphisms) could play an 289 
important role in the etiology of CRC (17). Interactions between the VDR gene and other genes have also 290 
been suggested. For instance, the androgen receptor gene could interact with the Fok1 VDR 291 
polymorphism, as well as with sunlight exposure and vitamin D intake (60). 292 
 293 
The question of the existence of an optimal vitamin D status is essential for medical practice and 294 
public health. In a meta-analysis performed in 2007 (10), Gorham et al. observed that a 50% lower risk of 295 
CRC was associated with a serum 25-hydroxyvitamin D level ≥1400 IU/l (33 ng/ml), compared to <509 296 
IU/l (12 ng/mL). Bischoff et al. (13) suggested that for several health outcomes (bone mineral density, 297 
colorectal cancer, among others), the most advantageous serum concentrations of 25-hydroxyvitamin D 298 
may be over 1272 IU/l (30 ng/mL) and probably in the range of 1527-1697 IU/l (36-40 ng/mL). The IOM 299 
committee recently stated that 20 ng/mL was the level needed for good bone health for practically all 300 
individuals (59). In an analysis including 30 studies reporting any adverse effect of high serum 25-301 
hydroxyvitamin D in adults, no reproducible toxicity was detected below 100 ng/ml (61). However, an 302 
increased risk at high levels (≥40 ng/ml) has been suggested for pancreatic cancer (62), and the potential 303 
for a J- or U-shaped association between vitamin D status and prostate and esophagus cancers has been 304 
suggested (63, 64). Thus, the precise optimal level of 25-hydroxyvitamin D remains to establish. Our data 305 
suggest that CRC cancer risk decreases with increasing levels of circulating 25-hydroxyvitamin D in a 306 
linear dose-dependent manner (at least within the 200-1800 IU/l range studied), although risk reduction 307 
could increase less rapidly above 1000 IU/l (24 ng/ml). However, since the range of 25-hydroxyvitamin D 308 
levels is limited in observational studies, information on high 25-hydroxyvitamin D levels in association 309 
with CRC risk remains scarce and needs further research. 310 
 311 
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Several factors (hormonal, anthropometric, dietary, environmental, etc.) have been suggested to 312 
interact with vitamin D on the risk of CRC. First, in a re-analysis of the Women’s Health Initiative 313 
Dietary Modification randomized control trial, a non-significant increased CRC risk was observed with 314 
the vitamin D/calcium supplementation among those who received estrogen therapy; whereas non-315 
significant reduced risk was observed among the placebo group of the estrogen trial (65), suggesting that 316 
estrogen therapy could interact with vitamin D/calcium on CRC risk. Second, Lagunova et al. suggested 317 
that the direct relationship between obesity and CRC risk could be partly mediated by a decrease of 25-318 
hydroxyvitamin D level with increasing body mass index (66). Next, it has been suggested that vitamin D 319 
and calcium may interact and that both may be required to decrease cancer risk (67). However, vitamin D 320 
remains associated with lower risk even after adjustment for calcium intake in several studies (47, 68), 321 
which is in favor of an independent effect of vitamin D. Nevertheless, the joint effect of both nutrients 322 
could be stronger that the sum of each independent effect (69). In the Health professionals follow-up 323 
study (47), the inverse association between 25-hydroxyvitamin D and CRC risk was statistically 324 
significant only in men with calcium intake above 885 mg/d. However, the opposite was observed in the 325 
Nurses' Health Study (47). No interaction was detected between dietary calcium and circulating 25-326 
hydroxyvitamin D level in the EPIC cohort (5). Several studies also investigated potential interactions 327 
between VDR polymorphisms and calcium and vitamin D intakes or status. An American study observed 328 
a significant 40% reduction in risk of rectal cancer for the SS (polyA) or BB (BsmI) VDR genotypes 329 
when calcium intake was low (70). The positive association between the ff genotype and CRC risk could 330 
be stronger among individuals with lower calcium intake (50). However, the opposite was observed in a 331 
large Scottish case-control study (19). Finnaly, in the EPIC study, Jenab et al. observed that the inverse 332 
CRC risk association of higher 25-hydroxyvitamin D was stronger at lower intakes of retinol (5). This 333 
interaction was not observed in the Health Professionals’ Follow-up and the Nurses' Health Studies (47). 334 
No interaction between 25-hydroxyvitamin D and alcohol was detected in the EPIC study (5). To date, 335 
data are still insufficient to draw firm conclusions on gene-diet-vitamin D status interactions and CRC. 336 
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Since we did not have original data, we were not able to systematically take into consideration or meta-337 
analyze the potential interactions between vitamin D and dietary, lifestyle, environmental and genetic 338 
effect modifiers. 339 
 340 
Original aspects of our study included an updated meta-analysis of prospective studies on CRC 341 
risk and vitamin D intake and status, with dose-response analyses, which strengthens the plausibility of a 342 
causal association. We also used non-linear dose-response models for 25-hydroxyvitamin D data, in order 343 
to investigate the potential for a threshold effect. Finally, we conducted meta-analyses of all single-344 
nucleotide VDR polymorphisms for which sufficient data was available. These complementary 345 
investigations allowed us to draw an overview of the relationship between vitamin D and CRC risk. 346 
Limitations of our study should be considered. First, three publications were not included in the 347 
meta-analyses due to insufficient data. These publications suggested either no association of CRC risk 348 
with the main VDR polymorphisms studied (22) and with dietary vitamin D intake (41), or an inverse 349 
association with dietary vitamin D intake (40). 350 
Second, it is possible that the observed relationships could be partly due to unmeasured or residual 351 
confounding. For instance, CRC risk was statistically significantly associated with dietary but not total 352 
vitamin D intake in dose-response analyses. This could be related to the fact that several medical 353 
conditions (among which some may be cancer precursors) may motivate the subjects (rightly or wrongly) 354 
to take supplements (71). In addition, there is compelling evidence in the literature that soy intake can 355 
influence the metabolism of vitamin D (72) and therefore may be a potential confounder. To our 356 
knowledge, none of the included study adjusted their analyses on soy or isoflavone intake or 357 
phytoestrogen supplement use. Besides, most studies on vitamin D intake could not control for sun 358 
exposure. This lack of data on sun exposure was compensated by the consideration of studies based on a 359 
biomarker of vitamin D status. However, the concentration of 25-hydroxyvitamin D in serum/plasma is 360 
considered as an accurate biomarker of vitamin D status (73), but a single cross-sectional measurement 361 
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(as done in all studies reviewed) does not take into account potential seasonal variations and could lead to 362 
non-differential classification bias. Nevertheless, most of the studies included in this meta-analysis 363 
adjusted for known confounding factors such as age, body mass index, smoking, alcohol, physical 364 
activity, red/processed meat intake, energy intake, and season of blood draw (for studies on vitamin D 365 
status). Beyond a potential confounding effect, season of blood collection may also interact with vitamin 366 
D status on the risk of CRC. In the Health professionals’ follow-up study, the relationship between 25-367 
hydroxyvitamin D and CRC risk was statistically significant for subjects whose blood collection occurred 368 
during the winter, but not during the summer (47). In the Nurses' Health Study, 25-hydroxyvitamin D was 369 
inversely associated with CRC risk only in areas with >335 langleys/day of UV light (36). 370 
Next, the imperfections associated with published information may constitute limitations of the 371 
meta-analyses. Notably, some limitations are specific to studies based on dietary data collection. The 372 
associations estimated in our meta-analysis were weak. Measurement errors in the assessment of 373 
dietary/supplemental intake and uncertainty of information used from food composition tables are known 374 
to bias estimates. However, since we included only prospective studies, the measurement errors would 375 
most likely be non-differential. Besides, the prospective design of the included studies also minimized the 376 
possibility of recall or selection bias. Dietary changes after baseline may, however, attenuate associations 377 
between dietary intake of vitamin D and cancer risk, as studies generally considered only baseline intake.  378 
Finally, in some analyses, our statistical power was limited when investigating associations with 379 
specific outcome subtypes (i.e., proximal and distal colon cancer) and/or specific exposures (i.e., 380 
supplemental vitamin D intake). Similarly, other single-nucleotide VDR polymorphisms such as tru91 or 381 
other variants (22, 52) have also been investigated in association with CRC risk, but to date, we were not 382 
able to perform meta-analyses on these variants due to insufficient data. 383 
 384 
Experimental studies support a protective effect of vitamin D on CRC. Some animal studies 385 
indicated that vitamin D status may influence growth of intestinal tumors (74-77). Vitamin D status 386 
 American Association for Cancer Research Copyright © 2011 
 on March 7, 2011cebp.aacrjournals.orgDownloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
Author Manuscript Published OnlineFirst on March 4, 2011; DOI:10.1158/1055-9965.EPI-10-1141
 17
modulates various genes in the colorectal mucosa that may influence cancer risk (69, 78). In humans, 387 
vitamin D may induce differentiation and apoptosis (79, 80), both in colorectal adenoma or cancer cells 388 
(81) and in the normal colorectal epithelium (82-84). 389 
 390 
In conclusion, the quantitative summary of the existing evidence from prospective cohort studies 391 
supports a modest although significant influence of vitamin D on colorectal carcinogenesis. The 392 
conclusions are supported by analysis on vitamin D intake but also on a biomarker of vitamin D status 393 
and on a VDR polymorphism. Available studies in vitamin D supplementation did not provide evidence 394 
of a benefit beyond that observed for dietary intake of vitamin D. Randomized controlled trials may more 395 
definitively establish a causal association, but the current data are sparse and inconclusive (85, 86) and 396 
long follow-up time will be needed before a substantial number of CRC cases could be identified in 397 
ongoing or future trials. So far, recommendations for CRC prevention should still mainly rely on the 398 
results of prospective observational studies.  399 
Given the potential benefits from vitamin D against CRC, further research should be a priority. 400 
Beyond the protective effect on CRC risk suggested by this meta-analysis, vitamin D is implicated in fall 401 
and fracture prevention and dental health, and may also reduce incident hypertension and cardiovascular 402 
mortality and convey immune-modulatory and anti-inflammatory benefits (87). This underlines the public 403 
health importance of reaching and maintaining an optimal vitamin D status at all life stages. 404 
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Table 1. Summary relative risks of meta-analyses for the associations of colorectal, colon and rectum cancer with vitamin D intake and status (dose-response analyses) 
and vitamin D receptor polymorphisms 
 
  Colorectal cancer Colon cancer Rectum cancer 
 Summary RR (95% CI) n I2, Pheterogeneity  Summary RR (95% CI) n I2, Pheterogeneity  Summary RR (95% CI) n I2, Pheterogeneity  
Vitamin D Intake (for an increase of 100 IU/day)       
   Dietary vitamin D             0.95 (0.93-0.98) 10 11.0%, P =0.34 0.97 (0.92-1.02) 8 0.0%, P =0.66 0.91 (0.77-1.08) 6 58.9%, P =0.03 
        Included studies (4-7, 26, 42-45, 88) (4, 5, 26-28, 42-44) (4, 5, 26, 42-44) 
   Supplemental vitamin D    0.93 (0.88-0.98) 2 0.0%, P =0.98    
        Included studies    (27, 28)    
   Total vitamin D              0.98 (0.95-1.01) 5 61.7%, P =0.034 0.93 (0.90-0.98) 4 49.5%, P =0.12 0.99 (0.94-1.04) 3 5.6%, P =0.35 
        Included studies (7, 26, 27, 30, 42, 45) (26-28, 42) (26, 30, 42) 
Biomarker of vitamin D status (for an increase of 100 IU/l) 
   25-hydroxyvitamin D        0.96 (0.94-0.97) 6 0.0%, P =0.81 0.95 (0.92-0.995) 6 47.9%, P =0.09 0.95 (0.86-1.05) 5 66.7%, P =0.02 
        Included studies (5, 12, 46, 47, 89) (5, 46, 47, 89, 90) (5, 46, 47, 89) 
Vitamin D receptor polymorphisms          
   FokI:      fF vs. FF 1.03 (0.87-1.22) 10 71.3%, P <0.0001 1.04 (0.79-1.36) 4 70.9%, P =0.02 1.01 (0.82-1.23) 3 15.5%, P =0.31 
                 Included studies (19, 21, 48-55) (21, 50, 56, 57) (21, 50, 51) 
                 ff vs. FF 0.98 (0.74-1.30) 10 80.8%, P <0.0001 1.26 (0.76-2.11) 4 85.7%, P <0.0001 1.03 (0.80-1.34) 3 13.0%, P =0.32 
                 Included studies (19, 21, 48-55) (21, 50, 56, 57) (21, 50, 51) 
   BsmI:     Bb vs. bb 0.81 (0.64-1.02) 9 86.8%, P <0.0001 1.01 (0.89-1.14) 2 0.0%, P =0.96 0.97 (0.70-1.33) 3 55.8%, P =0.10 
                 Included studies (19-21, 48, 49, 51, 52, 91, 92) (21, 51) (21, 51, 93) 
                 BB vs. bb 0.57 (0.36-0.89) 8 94.0%, P <0.0001 0.82 (0.66-1.02) 2 22.4%, P =0.26 0.95 (0.76-1.20) 3 0.0%, P =0.97 
                 Included studies (19-21, 48, 51, 52, 91, 92) (21, 51) (21, 51, 93) 
   TaqI:      Tt vs. TT 1.00 (0.74-1.35) 5 45.9%, P =0.12 1.04 (0.78-1.39) 2 0.0%, P =0.75    
                 Included studies (20, 49, 52, 55, 58) (57, 94)    
                 tt vs. TT 1.34 (0.80-2.24) 4 64.7%, P =0.04 0.98 (0.36-2.66) 2 86.1%, P =0.007    
                 Included studies (20, 52, 55, 58) (57, 94)    
   Cdx2:     Cc vs. cc 1.09 (1.001-1.18) 4 0.0%, P =0.80 1.04 (0.91-1.20) 2 0.0%, P =0.90    
                 Included studies (19, 20, 52, 95) (57, 95)    
                  CC vs. cc 1.11 (0.94-1.32) 4 0.0%, P =0.98 1.43 (0.76-2.68) 2 52.1%, P =0.15    
                 Included studies (19, 20, 52, 95) (57, 95)    
   PolyA:     LS vs. LL 0.93 (0.82-1.06) 2 0.0%, P =0.62       
                 Included studies (70, 96, 97)       
                  SS vs. LL 0.84 (0.66-1.06) 2 0.0%, P =0.35       
                 Included studies (70, 96, 97)       
   ApaI:       Aa vs. aa 0.95 (0.80-1.13) 5 32.2%, P =0.21       
                 Included studies (19, 20, 49, 52, 58)       
                  AA vs. aa 0.91 (0.67-1.23) 5 65.0%, P =0.02       
                 Included studies (19, 20, 49, 52, 58)       
Note: n denotes the number of studies included. 
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Figure legends 
 
Figure 1. Flow-chart of study selection for the association of vitamin D intake and status 
(prospective studies) and VDR polymorphisms with colorectal cancer (up until June 2010) 
 
Figure 2. Dose-response meta-analyses on dietary and total (dietary + supplemental) vitamin D 
intake, circulating 25-hydroxyvitamin D and risk of colorectal, colon and rectal cancer 
A. Dietary vitamin D (for an increase of 100 IU/d) 
B. Total vitamin D (for an increase of 100 IU/d) 
C. Circulating 25-hydroxyvitamin D (for an increase of 100 IU/l) 
 
Figure 3. Non-linear dose-response meta-analyses on circulating 25-hydroxyvitamin D and risk 
of colorectal cancer 
 
Figure 4. Meta-analyses on BsmI vitamin D receptor polymorphism and risk of colorectal cancer 
A. Bb (heterozygous type) vs. bb (wild type) 
B. BB (homozygous mutant type) vs. bb (wild type) 
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57000 records identified through multiple databases 
and handsearch 
3962 full-text articles retrieved and assessed for 
inclusion 
1141 publications included in the systematic 
literature review (SLR) 
50 publications examined the relationship between 
vitamin D intake, status or VDR polymorphisms 
and colorectal cancer 
42 publications included in the meta-analyses of cancer incidence 
15 publications (12 studies) on dietary vitamin D intake 
8 publications (6 studies) on supplemental vitamin D intake 
8 publications (6 studies) on total vitamin D intake 
6 publications (7 studies) on 25-hydroxyvitamin D 
23 publications (17 studies) on VDR polymorphisms 
53038 records excluded on the basis of title and 
abstract 
2821 articles excluded for not fulfilling the 
inclusion criteria 
1472 no original data/reviews 
841 did not report on the associations of 
interest 
321 non peer-reviewed articles/commentary 
179 meta-analyses/pooled/migrant studies/case 
reports 
8 articles with duplicate data 
8 publications excluded from the meta-analyses  
1 component study of a multi-center cohort  
2 superseded publications 
1 published on cancer deaths only 
3 publications did not provide 
sufficient/suitable data to include 
1 published on haplotypes for VDR, not found 
in other publications 
1091 publications reported on exposures other than 
vitamin D intake, status or VDR polymorphisms / 
studies on adenomas / not a prospective design (for 
intake and status) 
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A.          B.  
 
.
.
.
Colorectal cancer
Jenab
Ishihara
Park
McCarl
Lin
McCullough
Terry
Jarvinen
Pietinen
Martinez
Subtotal  (I-squared = 11.0%, p = 0.342)
Colon cancer
Jenab
Ishihara
McCullough
Terry
Jarvinen
Kearney
Martinez
Bostick
Subtotal  (I-squared = 0.0%, p = 0.656)
Rectal cancer
Jenab
Ishihara
McCullough
Terry
Jarvinen
Martinez
Subtotal  (I-squared = 58.9%, p = 0.033)
Author
2010
2008
2007
2006
2005
2003
2002
2001
1999
1996
2010
2008
2003
2002
2001
1996
1996
1993
2010
2008
2003
2002
2001
1996
Year
0.90 (0.77, 1.05)
1.01 (0.94, 1.07)
0.91 (0.85, 0.98)
0.94 (0.91, 0.97)
1.00 (0.86, 1.17)
0.94 (0.84, 1.05)
1.04 (0.87, 1.23)
1.58 (0.87, 2.84)
0.99 (0.85, 1.15)
0.94 (0.86, 1.03)
0.95 (0.93, 0.98)
0.94 (0.78, 1.13)
0.97 (0.87, 1.07)
0.89 (0.77, 1.03)
1.17 (0.94, 1.44)
1.18 (0.50, 2.76)
0.95 (0.83, 1.10)
0.98 (0.88, 1.10)
1.00 (0.88, 1.14)
0.97 (0.92, 1.02)
0.82 (0.63, 1.07)
0.96 (0.82, 1.11)
1.10 (0.86, 1.41)
0.80 (0.60, 1.07)
2.22 (0.99, 4.97)
0.73 (0.57, 0.92)
0.91 (0.77, 1.08)
RR (95% CI)
3.23
15.73
13.77
43.90
3.14
5.84
2.51
0.22
3.21
8.46
100.00
7.32
24.70
13.05
5.80
0.36
13.10
19.77
15.90
100.00
17.68
24.97
18.52
16.02
3.81
19.00
100.00
Weight
%
  
1.55 2.5         
.
.
.
Colorectal cancer
Park
Lin
McCullough
Martinez
Bostick;Zheng
Subtotal  (I-squared = 61.7%, p = 0.034)
Colon cancer
McCullough
Kearney
Martinez
Bostick
Subtotal  (I-squared = 49.5%, p = 0.115)
Rectal cancer
McCullough
Zheng
Martinez
Subtotal  (I-squared = 5.6%, p = 0.347)
Author
2007
2005
2003
1996
1993;1998
2003
1996
1996
1993
2003
1998
1996
Year
0.96 (0.93, 0.99)
1.07 (0.99, 1.16)
0.96 (0.92, 0.99)
1.00 (0.97, 1.03)
0.96 (0.91, 1.01)
0.98 (0.95, 1.01)
0.89 (0.84, 0.94)
0.92 (0.87, 0.99)
0.96 (0.91, 1.01)
0.97 (0.91, 1.04)
0.93 (0.90, 0.98)
1.00 (0.92, 1.10)
0.94 (0.87, 1.02)
1.03 (0.94, 1.13)
0.99 (0.94, 1.04)
RR (95% CI)
25.85
10.25
21.67
25.68
16.55
100.00
26.20
23.56
28.73
21.51
100.00
31.30
37.31
31.39
100.00
Weight
%
  
1.8 1.25
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C. 
.
.
.
Colorectal cancer
Jenab
Woolcott
Otani
Wu (HPFS)
Wu (NHS)
Tangrea
Subtotal  (I-squared = 0.0%, p = 0.809)
Colon cancer
Jenab
Otani
Wu (HPFS)
Wu (NHS)
Tangrea
Braun
Subtotal  (I-squared = 47.9%, p = 0.087)
Rectal cancer
Jenab
Otani
Wu (HPFS)
Wu (NHS)
Tangrea
Subtotal  (I-squared = 66.7%, p = 0.017)
Author
2010
2010
2007
2007
2007
1997
2010
2007
2007
2007
1997
1995
2010
2007
2007
2007
1997
Year
0.96 (0.94, 0.98)
0.95 (0.89, 1.01)
0.99 (0.91, 1.07)
0.96 (0.89, 1.02)
0.92 (0.86, 0.99)
0.98 (0.92, 1.04)
0.96 (0.94, 0.97)
0.94 (0.92, 0.97)
1.06 (0.96, 1.17)
0.88 (0.82, 0.96)
0.93 (0.86, 1.01)
0.99 (0.92, 1.07)
0.96 (0.81, 1.13)
0.95 (0.92, 1.00)
0.98 (0.95, 1.02)
0.79 (0.66, 0.95)
1.20 (0.98, 1.48)
0.76 (0.58, 1.00)
0.96 (0.87, 1.07)
0.95 (0.86, 1.05)
RR (95% CI)
67.43
8.13
4.29
6.45
6.34
7.37
100.00
33.20
12.11
15.78
15.93
17.53
5.45
100.00
34.05
16.11
14.28
9.57
26.00
100.00
Weight
%
  
1.55 1.6  
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A.                B. 
 
   
.
.
.
Colorectal cancer
Hughes
Jenab
Li
Parisi
Theodoratou
Flugge
Kadiyska
Slattery
Park
Subtotal  (I-squared = 86.8%, p = 0.000)
Colon cancer
Jenab
Slattery
Subtotal  (I-squared = 0.0%, p = 0.962)
Rectal cancer
Jenab
Slattery
Speer
Subtotal  (I-squared = 55.8%, p = 0.104)
Author
2010
2009
2009
2008
2008
2007
2007
2007
2006
2009
2007
2009
2007
2001
Year
Czech Republic
Europe
China
Spain
UK
Russia
Bulgaria
USA
Korea
Europe
USA
Europe
USA
Hungary
Country
1.02 (0.80, 1.30)
1.06 (0.87, 1.28)
0.10 (0.06, 0.19)
1.02 (0.61, 1.68)
0.88 (0.79, 0.99)
0.95 (0.66, 1.38)
0.48 (0.23, 1.00)
0.96 (0.85, 1.09)
1.36 (0.78, 2.37)
0.81 (0.64, 1.02)
1.00 (0.78, 1.28)
1.01 (0.87, 1.17)
1.01 (0.89, 1.14)
1.28 (0.91, 1.79)
0.88 (0.72, 1.08)
0.65 (0.32, 1.36)
0.97 (0.70, 1.33)
RR (95% CI)
13.40
14.16
7.66
8.98
15.16
11.23
6.08
15.07
8.25
100.00
26.16
73.84
100.00
36.30
49.08
14.63
100.00
Weight
%
  
1.25 2.5      
.
.
.
Colorectal cancer
Hughes
Jenab
Li
Parisi
Theodoratou
Flugge
Kadiyska
Slattery
Subtotal  (I-squared = 94.0%, p = 0.000)
Colon cancer
Jenab
Slattery
Subtotal  (I-squared = 22.4%, p = 0.256)
Rectal cancer
Jenab
Slattery
Speer
Subtotal  (I-squared = 0.0%, p = 0.972)
Author
2010
2009
2009
2008
2008
2007
2007
2007
2009
2007
2009
2007
2001
Year
Czech Republic
Europe
China
Spain
UK
Russia
Bulgaria
USA
Europe
USA
Europe
USA
Hungary
Country
0.93 (0.66, 1.30)
0.76 (0.59, 0.98)
0.02 (0.01, 0.03)
0.89 (0.44, 1.80)
0.93 (0.80, 1.09)
1.10 (0.65, 1.87)
0.60 (0.26, 1.41)
0.90 (0.76, 1.06)
0.57 (0.36, 0.89)
0.69 (0.45, 0.95)
0.88 (0.72, 1.08)
0.82 (0.66, 1.02)
0.97 (0.62, 1.49)
0.94 (0.70, 1.25)
1.04 (0.44, 2.49)
0.95 (0.76, 1.20)
RR (95% CI)
13.63
14.11
10.49
10.83
14.53
12.25
9.67
14.49
100.00
28.49
71.51
100.00
28.30
64.46
7.24
100.00
Weight
%
  
1.25 2.5  
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